Printed From:

Last update: February 2019

Sanofi has additional clinical trials for Praluent including:

ODYSSEY DM-Insulin [NCT02585778]1

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Praluent in insulin treated patients with type 1 or type 2 diabetes and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.

For more information please see clinicaltrials.gov.

 

ODYSSEY DM -Dyslipidaemia [NCT02642159]2

A randomized, open-label, parallel group study to evaluate the efficacy and safety of Praluent versus usual care in patients with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.

For more information on these trials and other trials involving Praluent please see clinicaltrials.gov.

References

  1. ClinicalTrials.gov NCT02585778. Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin).
  2. ClinicalTrials.gov NCT02642159. Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)